The evolving role of etoposide in the management of lymphomas and hodgkin's disease

Susan E. O';Reilly, Paul Klimo, Joseph M. Connors

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Etoposide, a derivative of epipodophyllotoxin, is one of the most important new drugs that was introduced into the management of the malignant lymphomas during the past decade. A growing number of specific protocols include this useful agent in the management of malignant lymphoma, both at the time of primary treatment and at relapse. The broad activity of etoposide across several histologic subtypes of malignant lymphoma and Hodgkin';s disease indicates a potential that is only now being fully exploited. Used according to optimal doses and schedules, etoposide has single‐agent activity that rivals earlier drugs such as the alkylating agents and doxorubicin. Functioning as a protein synthesis and topoisomerase II inhibitor, it offers the potential for non–cross‐resistant cytotoxicity. After a brief comment on the single‐agent activity of etoposide, this report will focus on the integration of etoposide into multiagent protocols used in the primary treatment of malignant lymphoma and Hodgkin';s disease. The specific findings from protocols such as prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide‐cytarabine, bleomycin, vincristine, and methotrexate (Pro‐MACE‐Cyta BOM) (US National Cancer Institute [NCI]) and etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP‐B) (Vancouver) for the primary treatment of malignant lymphoma, and vinblastine, etoposide, cyclophosphamide, doxorubicin, bleomycin, vincristine, and prednisone (VECABOP) (Vancouver) for the treatment of previously untreated patients with advanced Hodgkin';s disease will be discussed.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalCancer
Volume67
Issue number1 S
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Etoposide
Hodgkin Disease
Lymphoma
Doxorubicin
Bleomycin
Vincristine
Prednisone
Cyclophosphamide
Methotrexate
Podophyllotoxin
Topoisomerase II Inhibitors
National Cancer Institute (U.S.)
Vinblastine
Alkylating Agents
Therapeutics
Pharmaceutical Preparations
Appointments and Schedules
Recurrence
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The evolving role of etoposide in the management of lymphomas and hodgkin's disease. / O';Reilly, Susan E.; Klimo, Paul; Connors, Joseph M.

In: Cancer, Vol. 67, No. 1 S, 01.01.1991, p. 271-280.

Research output: Contribution to journalArticle

O';Reilly, Susan E. ; Klimo, Paul ; Connors, Joseph M. / The evolving role of etoposide in the management of lymphomas and hodgkin's disease. In: Cancer. 1991 ; Vol. 67, No. 1 S. pp. 271-280.
@article{76d54dff64144794897f9aee05ca7b5b,
title = "The evolving role of etoposide in the management of lymphomas and hodgkin's disease",
abstract = "Etoposide, a derivative of epipodophyllotoxin, is one of the most important new drugs that was introduced into the management of the malignant lymphomas during the past decade. A growing number of specific protocols include this useful agent in the management of malignant lymphoma, both at the time of primary treatment and at relapse. The broad activity of etoposide across several histologic subtypes of malignant lymphoma and Hodgkin';s disease indicates a potential that is only now being fully exploited. Used according to optimal doses and schedules, etoposide has single‐agent activity that rivals earlier drugs such as the alkylating agents and doxorubicin. Functioning as a protein synthesis and topoisomerase II inhibitor, it offers the potential for non–cross‐resistant cytotoxicity. After a brief comment on the single‐agent activity of etoposide, this report will focus on the integration of etoposide into multiagent protocols used in the primary treatment of malignant lymphoma and Hodgkin';s disease. The specific findings from protocols such as prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide‐cytarabine, bleomycin, vincristine, and methotrexate (Pro‐MACE‐Cyta BOM) (US National Cancer Institute [NCI]) and etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP‐B) (Vancouver) for the primary treatment of malignant lymphoma, and vinblastine, etoposide, cyclophosphamide, doxorubicin, bleomycin, vincristine, and prednisone (VECABOP) (Vancouver) for the treatment of previously untreated patients with advanced Hodgkin';s disease will be discussed.",
author = "O';Reilly, {Susan E.} and Paul Klimo and Connors, {Joseph M.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19910101)67:1+<271::AID-CNCR2820671311>3.0.CO;2-L",
language = "English (US)",
volume = "67",
pages = "271--280",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1 S",

}

TY - JOUR

T1 - The evolving role of etoposide in the management of lymphomas and hodgkin's disease

AU - O';Reilly, Susan E.

AU - Klimo, Paul

AU - Connors, Joseph M.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Etoposide, a derivative of epipodophyllotoxin, is one of the most important new drugs that was introduced into the management of the malignant lymphomas during the past decade. A growing number of specific protocols include this useful agent in the management of malignant lymphoma, both at the time of primary treatment and at relapse. The broad activity of etoposide across several histologic subtypes of malignant lymphoma and Hodgkin';s disease indicates a potential that is only now being fully exploited. Used according to optimal doses and schedules, etoposide has single‐agent activity that rivals earlier drugs such as the alkylating agents and doxorubicin. Functioning as a protein synthesis and topoisomerase II inhibitor, it offers the potential for non–cross‐resistant cytotoxicity. After a brief comment on the single‐agent activity of etoposide, this report will focus on the integration of etoposide into multiagent protocols used in the primary treatment of malignant lymphoma and Hodgkin';s disease. The specific findings from protocols such as prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide‐cytarabine, bleomycin, vincristine, and methotrexate (Pro‐MACE‐Cyta BOM) (US National Cancer Institute [NCI]) and etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP‐B) (Vancouver) for the primary treatment of malignant lymphoma, and vinblastine, etoposide, cyclophosphamide, doxorubicin, bleomycin, vincristine, and prednisone (VECABOP) (Vancouver) for the treatment of previously untreated patients with advanced Hodgkin';s disease will be discussed.

AB - Etoposide, a derivative of epipodophyllotoxin, is one of the most important new drugs that was introduced into the management of the malignant lymphomas during the past decade. A growing number of specific protocols include this useful agent in the management of malignant lymphoma, both at the time of primary treatment and at relapse. The broad activity of etoposide across several histologic subtypes of malignant lymphoma and Hodgkin';s disease indicates a potential that is only now being fully exploited. Used according to optimal doses and schedules, etoposide has single‐agent activity that rivals earlier drugs such as the alkylating agents and doxorubicin. Functioning as a protein synthesis and topoisomerase II inhibitor, it offers the potential for non–cross‐resistant cytotoxicity. After a brief comment on the single‐agent activity of etoposide, this report will focus on the integration of etoposide into multiagent protocols used in the primary treatment of malignant lymphoma and Hodgkin';s disease. The specific findings from protocols such as prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide‐cytarabine, bleomycin, vincristine, and methotrexate (Pro‐MACE‐Cyta BOM) (US National Cancer Institute [NCI]) and etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (VACOP‐B) (Vancouver) for the primary treatment of malignant lymphoma, and vinblastine, etoposide, cyclophosphamide, doxorubicin, bleomycin, vincristine, and prednisone (VECABOP) (Vancouver) for the treatment of previously untreated patients with advanced Hodgkin';s disease will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0025970652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025970652&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19910101)67:1+<271::AID-CNCR2820671311>3.0.CO;2-L

DO - 10.1002/1097-0142(19910101)67:1+<271::AID-CNCR2820671311>3.0.CO;2-L

M3 - Article

VL - 67

SP - 271

EP - 280

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1 S

ER -